WILMINGTON, Del., Jan. 22, 2016 -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of Ooma Inc. (NYSE:OOMA)?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. announces that a complaint (the “Complaint”) has been filed in the Superior Court of the State of California on behalf of all persons or entities that purchased the common stock of Ooma Inc. (“Ooma” or the “Company”) (NYSE:OOMA) pursuant to the July 2015 initial public offering (“IPO”) of the Company’s stock.
The Complaint alleges that Ooma failed to disclose certain material information in the Registration Statement issued in connection with the IPO. Specifically, it is alleged that Ooma failed to disclose that certain large prior fiscal year sales to its largest outside reseller were not recurring; that the rate of customer terminations and failures to renew had increased significantly due to significant service outages in the Spring of 2015; and that technological issues in the Company’s lead generation business caused leads to get lost before they reached their intended targets.
As a consequence of these adverse factors, Ooma’s stock lost approximately half its value since the IPO, trading at approximately $6.50 per share, compared to its IPO price of $13 per share.
If you suffered a loss in Ooma and would like to obtain additional information, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail at [email protected]; or at http://rigrodskylong.com/investigations/ooma-inc-ooma/.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com


Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Instagram Outage Disrupts Thousands of U.S. Users
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Washington Post Publisher Will Lewis Steps Down After Layoffs
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 



